Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 18/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 0.66 |
| ▸ | CDK2 | P24941 | 1/20 | 0.66 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.66 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.66 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.66 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945592 | 0.93 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1546604 | 0.91 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1944548 | 0.88 | ADORA2B (0.80) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL242026 | 0.87 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1546037 | 0.87 | ADORA2B (0.84) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL243466 | 0.86 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1944561 | 0.84 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL6014164 | 0.83 | ADORA2B (0.80) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1944742 | 0.82 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1945326 | 0.82 | ADORA2A (1.00) | ADORA2BADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8609671-B2 | Method of inhibiting hepatic fibrosis as a result of liver replacement or repair using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8466129-B2 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2012-08-30 | — | — | US | disclosed |
| EP-1685132-B1 | Processes and intermediates for the preparation of purine derivatives useful in the treatment of (inter alia) cancer, asthma and diarrhea | GILEAD SCIENCES INC (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-1789053-B1 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8188099-B2 | Method of decreasing hepatotoxic side effects using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110184002-A1 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| EP-2311462-A1 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7795268-B2 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | GILEAD PALO ALTO, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | GILEAD SCIENCES, INC. | 2007-09-20 | — | — | US | disclosed |
| EP-1799221-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060281921-A1 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-7125993-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1685132-A1 | A sb 2B /sb ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060159627-A1 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006044610-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-03-16 | — | — | US | disclosed |
| WO-2005051951-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20040176399-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20060281921-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20040176399-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20110184002-A1 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.